First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer

Overview of attention for article published in EJNMMI Research, December 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 20 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 906 followers.

New article: First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer https://t.co/Nf25ClbKkk #livercancer #oncology https://t.co/4uDbHMiPY5

Reply Repost Favourite

New article: First experiences with (177)Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer https://t.co/pre4XKUfqL #prostatecancer #oncology https://t.co/yStX1IHtpn

Reply Repost Favourite